Related Experiment Videos

Properties of a protective protein antigen of Erysipelothrix rhusiopathiae

J F Timoney1, M M Groschup

  • 1Gluck Equine Research Center, University of Kentucky, Lexington.

Veterinary Microbiology
|November 1, 1993
PubMed

Insights

Antibodies targeting a 66-64 kDa protein from Erysipelothrix rhusiopathiae offer broad protection against infection, irrespective of serotype. This protein shows potential for developing new vaccine testing methods.

Area of Science:

  • Veterinary Microbiology
  • Immunology
  • Bacterial Pathogenesis

Background:

  • Erysipelothrix rhusiopathiae is a common bacterium found in vertebrate digestive systems.
  • Immunity against E. rhusiopathiae involves antibodies to a cell surface protein of 66-64 kDa.
  • Serotyping relies on polysaccharide antigens, indicating protein antigens may confer broader protection.

Purpose of the Study:

  • To investigate the protective immunity conferred by a 66-64 kDa protein from E. rhusiopathiae.
  • To determine if protection is serotype-specific.
  • To explore the immunogenicity of the 66-64 kDa protein when complexed with glycolipid.

Main Methods:

  • Mice were immunized with purified 66-64 kDa protein from E. rhusiopathiae strain T28 (serotype 2b).
  • Immunized mice were challenged with different E. rhusiopathiae strains (serotype 1a and serotype N).
  • Immunogenicity of the protein was assessed when complexed with glycolipid.

Main Results:

  • Immunization with the 66-64 kDa protein provided protection against challenge with heterologous serotypes (1a and N).
  • Protection was not limited to the homologous serotype, suggesting non-serotype-specific immunity.
  • The 66-64 kDa protein was most immunogenic when complexed with glycolipid, possibly due to adjuvant effects.

Conclusions:

  • The 66-64 kDa protein of E. rhusiopathiae is a promising candidate for a broadly protective vaccine antigen.
  • The non-serotype-specific nature of protection highlights the potential for a universal vaccine.
  • Further research correlating antibody titers with protection could lead to an in vitro assay for vaccine efficacy testing.

Related Concept Videos